Dermira Reports First Quarter 2016 Financial Results and Provides Corporate Update - Positive Topline Results for DRM01 Phase 2b Acne Trial Reported; Phase 3 Program Planning Underway - Announcement of Topline Results for DRM04 Phase 3 Hyperhidrosis Pivotal Trials Expected in...

Dermira Announces Positive Topline Phase 2b Clinical Trial Results for DRM01 in Patients with Facial Acne Vulgaris - Safety and Efficacy Data Confirm Results from Previous Phase 2a Trial - DRM01 Phase 3 Clinical Program Planning Underway - Management to Host Webcast and Conference Call Today at 5:30 a.m....

Dermira Completes Patient Enrollment for First CIMZIA(R) (Certolizumab Pegol) Phase 3 Clinical Trial in Psoriasis Program MENLO PARK, Calif., Oct. 12, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists...

Dermira Presents Data From DRM01 Phase 2a Trial at European Academy of Dermatology and Venereology MENLO PARK, Calif., Oct. 7, 2015 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and...